

Date: October 27, 2026

To,

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001.

National Stock Exchange of India Ltd.

Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

BSE Script Code: 531599

NSE Symbol: FDC

Sub: Press Release on Q2 - FY 2026-27 Results.

Dear Sir/Ma'am,

Please find attached herewith a Press Release issued in relation to the Unaudited Consolidated Financial Results of the Company for the Quarter and half year ended September 30, 2026.

Kindly take the same on record.

Thanking you,

Yours truly

For FDC Limited

VARSHAR Digitally signed by
ANI KATRE VARSHARANI KATRE
Date: 2026.10.27
19:13:50 +05'30'

Varsharani Katre

Company Secretary & Legal Head

M No.: FCS-8948

FDC Limited announces Q2 & H1 FY27 results

Domestic Formulations return to double-digit growth; International Formulations sustain momentum

Mumbai, October 27, 2026: FDC Limited (NSE: FDC, BSE: 531599, ISIN: INE258B01022) today announced its unaudited consolidated financial results for the second quarter and half-year ended September 30, 2026.

Key Highlights – Q2 FY27

- Revenue from operations of Rs. 572 crores, up 21.0% Y-o-Y
- Domestic Formulations grew 22.6% Y-o-Y, led by Electral and Enerzal, with Zifi returning to growth
- International Formulations grew 28.5% Y-o-Y in Q2 and 47.6% in H1 FY27
- EBITDA of Rs. 64 crores; EBITDA margin of 11.2%, against 7.1% in Q2 FY26
- FDC was the fastest-growing company among the top 25 corporates in the Indian Pharmaceutical Market in Q2 FY27 (Source: IQVIA Sep'26)

Consolidated Financial Results

(Rs. in crores)

Particulars	Q2 FY27	Q2 FY26	Y-o-Y Grw %	H1 FY27	H1 FY26	Y-o-Y Grw %
Revenue from Operations	572	473	21.0%	1,240	1,121	10.6%
EBITDA	64	34	90.2%	210	176	19.4%
<i>EBITDA Margin</i>	<i>11.2%</i>	<i>7.1%</i>		<i>16.9%</i>	<i>15.7%</i>	
PBT	65	38	71.7%	240	198	21.4%
PAT	49	28	72.9%	181	150	21.3%
EPS (Rs.)	3.01	1.75	72.2%	11.15	9.20	21.2%

*EBITDA excludes other income.

Revenue from operations for Q2 FY27 stood at Rs. 572 crores, a Y-o-Y increase of 21.0% over Rs. 473 crores in Q2 FY26. Growth was driven by a recovery in Domestic Formulations and continued growth in International Formulations. For H1 FY27, revenue from operations stood at Rs. 1,240 crores, up 10.6% from Rs. 1,121 crores in H1 FY26.

EBITDA for Q2 FY27 stood at Rs. 64 crores, against Rs. 34 crores in Q2 FY26, with the EBITDA margin at 11.2% against 7.1%. For H1 FY27, EBITDA stood at Rs. 210 crores (margin 16.9%), against Rs. 176 crores (15.7%) in H1 FY26.

Profit before tax for Q2 FY27 stood at Rs. 65 crores against Rs. 38 crores in Q2 FY26, and profit after tax stood at Rs. 49 crores against Rs. 28 crores. Earnings per share for the quarter were Rs. 3.01, against Rs. 1.75. For H1 FY27, profit after tax stood at Rs. 181 crores, against Rs. 150 crores in H1 FY26.

REGISTERED OFFICE

FDC House, C-11 & 12, Dalia Industrial Estate, Oshiwara Village, Off New Link Road, Andheri (West), Mumbai - 400 053, Maharashtra, INDIA.
 • Phones : +91-22-69107100 • E-mail : fdc@fdcindia.com • Website : www.fdcindia.com • CIN : L24239MH1940PLC003176

Business Segment-wise Sales Performance

(Rs. in crores)

Particulars	Q2 FY27	Y-o-Y Grw %	H1 FY27	Y-o-Y Grw %
Revenue from Operations	572	21.0%	1,240	10.6%
Domestic Formulations	467	22.6%	1,036	7.8%
International Formulations (US)	30	109.7%	65	99.7%
International Formulations (Non-US)	45	1.6%	83	22.8%
APIs	28	-4.8%	52	-4.0%

Domestic Formulations:

Domestic Formulations returned to growth in Q2 FY27, with revenue of Rs. 467 crores, up 22.6% Y-o-Y from Rs. 381 crores in Q2 FY26. The recovery was led by the Company's flagship brands. Electral and Enerzal continued their strong performance, while Zifi overcame the challenges of earlier quarters to grow.

For H1 FY27, Domestic Formulations revenue stood at Rs. 1,036 crores, up 7.8% Y-o-Y from Rs. 961 crores in H1 FY26. The strong Q2 more than offset the softer start to the year. Domestic Formulations accounted for approximately 84% of consolidated sales in the H1.

As per IQVIA secondary sales data, the Company recorded growth of 21.4% for the quarter and 8.2% for the MAT ended September 30, 2026. FDC was the fastest-growing company among the top 25 corporates in the Indian Pharmaceutical Market in Q2 FY27.

International Formulations:

International Formulations continued their growth trajectory in Q2 FY27, with sales of Rs. 75 crores, up 28.5% Y-o-Y from Rs. 58 crores in Q2 FY26. For H1 FY27, International Formulations sales rose 47.6% Y-o-Y to Rs. 148 crores, from Rs. 101 crores in H1 FY26. The segment contributed approximately 12% of consolidated sales.

APIs:

The API business recorded sales of Rs. 28 crores in Q2 FY27, against Rs. 30 crores in Q2 FY26 (-4.8% Y-o-Y).

For H1 FY27, API sales declined 4.0% Y-o-Y to Rs. 52 crores, from Rs. 54 crores in H1 FY26, mainly due to lower sales of one key molecule. The API business accounted for approximately 4% of consolidated sales.

REGISTERED OFFICE

ABOUT FDC LTD

FDC was established in the year 1936 as a partnership firm. This firm was incorporated as a Company in 1940, with the vision of building a world-class company while contributing to making the nation self-reliant in healthcare. To cite a few, FDC carries forward the flaming spirit of its first dream, achieving accreditations from the US-FDA, UK-MHRA, SAPHRA, and the UAE. FDC is a forerunner in the manufacturing and marketing of Oral Rehydration Salts (ORS), anti-infectives and ophthalmics. FDC has also set up globally approved, multi-location manufacturing facilities for Active Pharmaceutical Ingredients (APIs) as well as Finished Dosage Formulations. These facilities are located at Roha, Waluj and Sinnar in Maharashtra, Verna in Goa and Baddi in Himachal Pradesh. FDC markets more than 300 products in India and exports many of these to over 50 countries. FDC strives to explore, innovate and integrate solutions with modern technology, empowering talent and expanding healthcare horizons for a better quality of life for millions globally.

Disclaimer

Except for the historical information contained herein, statements in this press release and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve several risks and uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.

REGISTERED OFFICE

FDC House, C-11 & 12, Dalia Industrial Estate, Oshiwara Village, Off New Link Road, Andheri (West), Mumbai - 400 053, Maharashtra, INDIA.
• Phones : +91-22-69107100 • E-mail : fdc@fdcindia.com • Website : www.fdcindia.com • CIN : L24239MH1940PLC003176